Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
暂无分享,去创建一个
[1] Siegfried S. F. Leung,et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. , 2015, Journal of the American Chemical Society.
[2] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[3] A. Molla,et al. Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A. , 2013, Bioorganic & medicinal chemistry letters.
[4] W. M. Hewitt,et al. Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules. , 2017, Journal of medicinal chemistry.
[5] Fabrizio Giordanetto,et al. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. , 2014, Chemistry & biology.
[6] S. Pickett,et al. Increasing small molecule drug developability in sub-optimal chemical space , 2013 .
[7] A. C. Krueger,et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. , 2014, Journal of medicinal chemistry.
[8] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[9] R. Flisiak,et al. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection , 2016, Expert opinion on pharmacotherapy.
[10] M. Shalaeva,et al. High throughput method for the indirect detection of intramolecular hydrogen bonding. , 2014, Journal of medicinal chemistry.
[11] Bradley C Doak,et al. Cell permeability beyond the rule of 5. , 2016, Advanced drug delivery reviews.
[12] Anil Vasudevan,et al. Abbott Physicochemical Tiering (APT)--a unified approach to HTS triage. , 2012, Bioorganic & medicinal chemistry.
[13] N. Meanwell,et al. Characterizations of HCV NS5A replication complex inhibitors. , 2013, Virology.
[14] N. Meanwell,et al. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. , 2014, Journal of medicinal chemistry.
[15] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[16] G. Caron,et al. Updating molecular properties during early drug discovery. , 2017, Drug discovery today.
[17] Mary K Joseph,et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.
[18] K. R. Reddy,et al. Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy , 2016, Alimentary pharmacology & therapeutics.
[19] Matthew P Jacobson,et al. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.
[20] Paul D Leeson,et al. Molecular inflation, attrition and the rule of five. , 2016, Advanced drug delivery reviews.
[21] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[22] S. Vasavanonda,et al. Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir , 2004, Antimicrobial Agents and Chemotherapy.
[23] Bradley C Doak,et al. How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. , 2016, Journal of medicinal chemistry.
[24] M. Wendt. The Discovery of Navitoclax, a Bcl-2 Family Inhibitor , 2012 .
[25] M. Shalaeva,et al. Relationship between Passive Permeability and Molecular Polarity Using Block Relevance Analysis. , 2017, Molecular pharmaceutics.
[26] N. Meanwell,et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. , 2014, Journal of medicinal chemistry.
[27] Darren V S Green,et al. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. , 2011, Drug discovery today.
[28] A. Schinkel,et al. The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[29] Jerome Wielens,et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA , 2014, Scientific Reports.
[30] J. Kort,et al. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection , 2015, Antimicrobial Agents and Chemotherapy.
[31] Daniel M. Lowe,et al. Big Data from Pharmaceutical Patents: A Computational Analysis of Medicinal Chemists' Bread and Butter. , 2016, Journal of medicinal chemistry.
[32] Michael J Shapiro,et al. EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides. , 2014, ACS medicinal chemistry letters.
[33] J. Lubach,et al. The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199 , 2014, Drug Metabolism and Disposition.
[34] K. Maeda,et al. Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg. , 2016, Journal of pharmaceutical sciences.
[35] Nicholas A Meanwell,et al. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. , 2016, Chemical research in toxicology.
[36] Ulf Norinder,et al. Structural and conformational determinants of macrocycle cell permeability. , 2016, Nature chemical biology.
[37] Paul D. Leeson,et al. The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.
[38] Spiros Liras,et al. Improving on nature: making a cyclic heptapeptide orally bioavailable. , 2014, Angewandte Chemie.
[39] Michael A. Smith,et al. The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy , 2015, Expert opinion on drug safety.
[40] Cristiano Ruch Werneck Guimarães,et al. Use of 3D Properties to Characterize Beyond Rule-of-5 Property Space for Passive Permeation , 2012, J. Chem. Inf. Model..
[41] Nathan Brown,et al. Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules , 2012, J. Chem. Inf. Model..
[42] W Patrick Walters,et al. What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.
[43] Jan Kihlberg,et al. How Big Is Too Big for Cell Permeability? , 2017, Journal of medicinal chemistry.
[44] Thomas J. Vidmar,et al. Predicting Drug Absorption: How Nature Made It a Difficult Problem , 2002, Journal of Pharmacology and Experimental Therapeutics.
[45] Dima Kozakov,et al. How Proteins Bind Macrocycles , 2014, Nature chemical biology.
[46] Claudia S Neuhaus,et al. When barriers ignore the "rule-of-five". , 2016, Advanced drug delivery reviews.
[47] C. Rice,et al. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase , 2005, Nature.
[48] M. Hickey,et al. Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus , 2009, Journal of Virology.
[49] S. Vajda,et al. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. , 2016, Drug discovery today.
[50] A. Molla,et al. In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450 , 2014, Antimicrobial Agents and Chemotherapy.
[51] R. M. Owen,et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.
[52] Dolores Diaz,et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy , 2015, Science Translational Medicine.
[53] I. Tamai. Oral drug delivery utilizing intestinal OATP transporters. , 2012, Advanced drug delivery reviews.
[54] G. Gordon,et al. Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management. , 2014, Anticancer research.
[55] Fabrizio Giordanetto,et al. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.
[56] M. Otto,et al. Inhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimetics. , 2012, Bioorganic & medicinal chemistry letters.
[57] Paul D Leeson,et al. Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.
[58] A. Salem,et al. Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin Lymphoma , 2017, Journal of clinical pharmacology.
[59] T. Elbaz,et al. Safety of direct antiviral agents in the management of hepatitis C , 2016, Expert opinion on drug safety.
[60] David J. Craik,et al. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients , 2014, Proceedings of the National Academy of Sciences.
[61] Saul H Rosenberg,et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. , 2008, Journal of medicinal chemistry.